Collectively, these data demonstrate BCR signal rewiring in CLL cells suggesting that this is an adaptive response of the malignant cells in a resistance mechanism to chemoimmunotherapy. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.